The glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide is the most recently
approved agent of this drug class, and the only GLP-1RA currently available as both …

Obesity is a growing epidemic within the USA. Because weight gain is associated with an
increased risk of developing life-threatening comorbidities, such as hypertension or type 2 …

Background Metabolic–bariatric surgery delivers substantial weight loss and can induce
remission or improvement of obesity-related risks and complications. However, more robust …

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are attractive options for the
treatment of type 2 diabetes (T2D) because they effectively lower A1C and weight while …

Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is available as
monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 …

Background Given the unique phenotype of type 2 diabetes in Japanese patients, novel
therapies such as oral semaglutide require evaluation in this population. PIONEER 9 aimed …

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and
obesity for their high efficacy in controlling glycaemia and inducing body weight loss …

Abstract Losses of 5–10% or more of initial body weight are associated with improvements
in obesity-related comorbidities. However, attaining and sustaining this level of weight loss …

Background French national health care insurance system database has suggested 1–3
years use of glucagon like peptide-1 receptor agonists (GLP1RA)(exenatide, liraglutide and …

Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are recommended for glycaemic
management in patients with type 2 diabetes (T2D). Oral semaglutide, the first oral GLP …